Publications in collaboration with researchers from Gustave Roussy Cancer Campus (25)

2020

  1. Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer

    Nature Communications, Vol. 11, Núm. 1

  2. Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer (Nature Communications, (2020), 11, 1, (3819), 10.1038/s41467-020-17644-0)

    Nature Communications

2019

  1. Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake and Obesity

    Cell Metabolism, Vol. 30, Núm. 4, pp. 754-767.e9

2018

  1. Immune effectors responsible for the elimination of hyperploid cancer cells

    OncoImmunology, Vol. 7, Núm. 8

  2. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy

    OncoImmunology, Vol. 7, Núm. 6

2017

  1. Trial watch: Immune checkpoint blockers for cancer therapy

    OncoImmunology, Vol. 6, Núm. 11

2016

  1. Trial Watch: Immunotherapy plus radiation therapy for oncological indications

    OncoImmunology, Vol. 5, Núm. 9

  2. Trial Watch—Immunostimulation with cytokines in cancer therapy

    OncoImmunology, Vol. 5, Núm. 2

  3. Trial Watch—Oncolytic viruses and cancer therapy

    OncoImmunology, Vol. 5, Núm. 2

  4. Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

    OncoImmunology, Vol. 5, Núm. 6

2015

  1. Trial Watch: Adoptive cell transfer for oncological indications

    OncoImmunology, Vol. 4, Núm. 11

  2. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy

    OncoImmunology, Vol. 4, Núm. 4

  3. Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications

    OncoImmunology, Vol. 4, Núm. 4

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508

  2. Consensus guidelines for the detection of immunogenic cell death

    OncoImmunology, Vol. 3, Núm. 9

  3. Impact of myeloid cells on the efficacy of anticancer chemotherapy

    Current Opinion in Immunology, Vol. 30, Núm. 1, pp. 24-31

  4. Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy

    OncoImmunology, Vol. 3, Núm. 2

  5. Trial Watch: Toll-like receptor agonists in oncological indications

    OncoImmunology, Vol. 3, Núm. 7

  6. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy

    OncoImmunology, Vol. 3, Núm. 1

  7. Trial watch: Adoptive cell transfer for anticancer immunotherapy

    OncoImmunology, Vol. 3, Núm. 5